Seminars in Oncology
Volume 35, Supplement 3 , Pages S34-S43, June 2008

Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors

  • Joaquim Bellmunt

      Affiliations

    • University Hospital Del Mar, Barcelona, Spain.
    • Corresponding Author InformationAddress correspondence to Joaquim Bellmunt, MD, Medical Oncology Service, University Hospital del Mar, Paseo Maritimo 25-29, Barcelona 08003, Spain.
    • ,
  • Francois-Michel Delgado

      Affiliations

    • Institut de Recherche Pierre Fabre, Boulogne, France.
    • ,
  • Claude George

      Affiliations

    • Bristol-Myers Squibb, Princeton, NJ.

Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non–small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Bellmunt has no conflict of interest to declare. Dr Delgado is an employee of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine. Dr George is an employee of Bristol-Myers Squibb.

PII: S0093-7754(08)00021-3

doi:10.1053/j.seminoncol.2008.01.008

Seminars in Oncology
Volume 35, Supplement 3 , Pages S34-S43, June 2008

Article Tools